Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Breast Cancer Patient Meeting Likely To Examine Differences Between Early-Stage and Metastatic Experiences

This article was originally published in RPM Report

Executive Summary

In April, FDA’s patient focused drug development initiative will look at one of the most emotionally and politically fraught areas of advocacy: breast cancer. Here’s a look at what the agency is likely to hear.

Advertisement

Related Content

FDA Looking To Patient Advocates To Answer Benefit-Risk Questions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel